TMC Life Sciences Bhd 2024 AR2
The report highlights TMC Life Sciences Berhad's performance for the financial year ended 30 June 2024, marking its 30th anniversary. The company achieved an 11% increase in revenue to RM346.4 million and a 4% increase in net profit to RM40.6 million. Key achievements include Thomson Hospital Kota Damansara becoming the first in Southeast Asia to administer the drug Spinraza and obtaining ACHS International Accreditation. On sustainability, the company expanded its Scope 3 emissions tracking and reaffirmed its commitment to achieving net-zero carbon emissions by 2050.
Company: TMC Life Sciences Bhd
Sector: Healthcare & social services
Country: Malaysia
Year: 2024
Type: AR2
Pages: 208
Back to company
TMC Life Sciences Bhd
Annual Report
The report highlights TMC Life Sciences Berhad's performance for the financial year ended 30 June 2024, marking its 30th anniversary. The company achieved an 11% increase in revenue to RM346.4 million and a 4% increase in net profit to RM40.6 million. Key achievements include Thomson Hospital Kota Damansara becoming the first in Southeast Asia to administer the drug Spinraza and obtaining ACHS International Accreditation. On sustainability, the company expanded its Scope 3 emissions tracking and reaffirmed its commitment to achieving net-zero carbon emissions by 2050.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jul 1, 2023 - Jun 30, 2024
Fiscal Year
2024
Published
Nov 6, 2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees